$12
+0.05
(+0.42%)▲
Insights on Viridian Therapeutics Inc
Revenue is down for the last 7 quarters, 1.19M → 72.0K (in $), with an average decrease of 20.7% per quarter
Netprofit is up for the last 2 quarters, -66.86M → -48.54M (in $), with an average increase of 37.7% per quarter
In the last 1 year, Novo Nordisk A/s has given 72.6% return, outperforming this stock by 123.4%
0.58%
Downside
Day's Volatility :5.09%
Upside
4.53%
8.92%
Downside
52 Weeks Volatility :61.45%
Upside
57.67%
Period | Viridian Therapeutics Inc | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -37.01% | -1.0% | 0.0% |
6 Months | -32.89% | 9.6% | 0.0% |
1 Year | -51.75% | 11.0% | 0.0% |
3 Years | 12.89% | 18.5% | -22.6% |
Market Capitalization | 762.7M |
Book Value | $6.0 |
Earnings Per Share (EPS) | -4.49 |
Wall Street Target Price | 36.5 |
Profit Margin | 0.0% |
Operating Margin TTM | -77634.72% |
Return On Assets TTM | -29.24% |
Return On Equity TTM | -46.75% |
Revenue TTM | 288.0K |
Revenue Per Share TTM | 0.01 |
Quarterly Revenue Growth YOY | -26.5% |
Gross Profit TTM | -99.1M |
EBITDA | -237.3M |
Diluted Eps TTM | -4.49 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -3.7 |
EPS Estimate Next Year | -3.93 |
EPS Estimate Current Quarter | -1.1 |
EPS Estimate Next Quarter | -1.11 |
What analysts predicted
Upside of 204.17%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 8.4M | ↑ 109.49% |
Net Income | -32.7M | ↑ 23.35% |
Net Profit Margin | -389.97% | ↑ 272.33% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 4.5M | ↓ 46.8% |
Net Income | -42.4M | ↑ 29.71% |
Net Profit Margin | -950.91% | ↓ 560.94% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 1.1M | ↓ 76.46% |
Net Income | -111.0M | ↑ 161.63% |
Net Profit Margin | -10.6K% | ↓ 9618.99% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 3.0M | ↑ 182.19% |
Net Income | -79.4M | ↓ 28.44% |
Net Profit Margin | -2.7K% | ↑ 7889.64% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 1.8M | ↓ 40.2% |
Net Income | -125.4M | ↑ 57.96% |
Net Profit Margin | -7.1K% | ↓ 4398.97% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 314.0K | ↓ 82.28% |
Net Income | -237.7M | ↑ 89.51% |
Net Profit Margin | -75.7K% | ↓ 68632.23% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 105.0K | ↓ 91.21% |
Net Income | -42.5M | ↑ 51.66% |
Net Profit Margin | -40.5K% | ↓ 38134.81% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 98.0K | ↓ 6.67% |
Net Income | -68.0M | ↑ 60.09% |
Net Profit Margin | -69.4K% | ↓ 28954.69% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 72.0K | ↓ 26.53% |
Net Income | -55.1M | ↓ 19.08% |
Net Profit Margin | -76.5K% | ↓ 7041.7% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 72.0K | ↑ 0.0% |
Net Income | -47.7M | ↓ 13.44% |
Net Profit Margin | -66.2K% | ↑ 10281.95% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 72.0K | ↑ 0.0% |
Net Income | -66.9M | ↑ 40.29% |
Net Profit Margin | -92.9K% | ↓ 26666.67% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 72.0K | ↑ 0.0% |
Net Income | -48.5M | ↓ 27.4% |
Net Profit Margin | -67.4K% | ↑ 25441.67% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 66.1M | ↑ 26.04% |
Total Liabilities | 14.8M | ↑ 5.96% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 30.3M | ↓ 54.25% |
Total Liabilities | 14.5M | ↓ 1.99% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 131.3M | ↑ 333.73% |
Total Liabilities | 11.2M | ↓ 22.68% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 203.7M | ↑ 55.2% |
Total Liabilities | 16.0M | ↑ 42.57% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 435.1M | ↑ 113.58% |
Total Liabilities | 40.0M | ↑ 150.28% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 490.4M | ↑ 12.72% |
Total Liabilities | 48.4M | ↑ 20.92% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 435.1M | ↓ 1.25% |
Total Liabilities | 40.0M | ↑ 26.78% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 386.6M | ↓ 11.14% |
Total Liabilities | 36.1M | ↓ 9.83% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 351.5M | ↓ 9.1% |
Total Liabilities | 35.6M | ↓ 1.34% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 328.8M | ↓ 6.46% |
Total Liabilities | 45.2M | ↑ 26.88% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 490.4M | ↑ 49.18% |
Total Liabilities | 48.4M | ↑ 7.13% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 630.4M | ↑ 28.54% |
Total Liabilities | 47.9M | ↓ 1.14% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -26.8M | ↓ 4.7% |
Investing Cash Flow | -29.9M | ↓ 2992.36% |
Financing Cash Flow | 41.9M | ↓ 20.11% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -36.1M | ↑ 34.32% |
Investing Cash Flow | 28.2M | ↓ 194.38% |
Financing Cash Flow | 70.0K | ↓ 99.83% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -29.8M | ↓ 17.41% |
Investing Cash Flow | -50.5M | ↓ 278.85% |
Financing Cash Flow | 101.3M | ↑ 144630.0% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -54.6M | ↑ 83.29% |
Investing Cash Flow | -74.3M | ↑ 47.17% |
Financing Cash Flow | 125.3M | ↑ 23.65% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -93.8M | ↑ 71.92% |
Investing Cash Flow | -115.1M | ↑ 54.96% |
Financing Cash Flow | 322.2M | ↑ 157.23% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -34.0M | ↑ 64.71% |
Investing Cash Flow | -180.6M | ↓ 523.44% |
Financing Cash Flow | 26.0M | ↓ 91.06% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -62.0M | ↑ 82.05% |
Investing Cash Flow | -13.3M | ↓ 92.64% |
Financing Cash Flow | 8.2M | ↓ 68.46% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -45.2M | ↓ 27.04% |
Investing Cash Flow | 40.7M | ↓ 406.23% |
Financing Cash Flow | 3.1M | ↓ 62.6% |
Sell
Neutral
Buy
Viridian Therapeutics Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Viridian Therapeutics Inc | -23.03% | -32.89% | -51.75% | 12.89% | 12.89% |
Moderna, Inc. | 21.03% | 85.08% | 14.68% | -28.27% | 659.22% |
Regeneron Pharmaceuticals, Inc. | 3.22% | 20.18% | 31.88% | 93.3% | 227.58% |
Novo Nordisk A/s | 8.85% | 34.38% | 71.83% | 235.07% | 463.44% |
Vertex Pharmaceuticals Incorporated | 16.81% | 34.1% | 40.6% | 123.97% | 174.53% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Viridian Therapeutics Inc | NA | NA | NA | -3.7 | -0.47 | -0.29 | NA | 6.0 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.14 | -0.38 | -0.16 | NA | 33.47 |
Regeneron Pharmaceuticals, Inc. | 28.89 | 28.89 | 1.46 | 44.13 | 0.15 | 0.08 | NA | 250.15 |
Novo Nordisk A/s | 46.97 | 46.97 | 2.36 | 3.5 | 1.0 | 0.25 | 0.01 | 22.18 |
Vertex Pharmaceuticals Incorporated | 29.59 | 29.59 | 0.53 | 17.08 | 0.24 | 0.13 | NA | 71.8 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Viridian Therapeutics Inc | Buy | $762.7M | 12.89% | NA | 0.0% |
Moderna, Inc. | Buy | $54.6B | 659.22% | 24.73 | -115.82% |
Regeneron Pharmaceuticals, Inc. | Buy | $108.0B | 227.58% | 28.89 | 29.45% |
Novo Nordisk A/s | Buy | $602.6B | 463.44% | 46.97 | 36.55% |
Vertex Pharmaceuticals Incorporated | Buy | $117.5B | 174.53% | 29.59 | 39.46% |
FMR Inc
Paradigm Biocapital Advisors LP
State Street Corporation
BlackRock Inc
Perceptive Advisors LLC
Deep Track Capital, LP
miragen therapeutics, inc., (nasdaq: mgen), is a biopharmaceutical company discovering and developing innovative microrna (mirna)-targeting therapies to improve human health, specifically in disease areas of high unmet medical need. the company leverages in-house expertise in mirna biology, oligonucleotide chemistry, and drug development to evaluate and advance best-in-class technologies and high-potential drug candidates for its own pipeline or in conjunction with strategic partners. at miragen, we recognize the importance of creating strategic relationships within the biotech and pharmaceutical industries and with academic institutions globally. this collaborative approach is making important contributions in our efforts to create mirna-targeting therapies. miragen’s areas of focus include hematological malignancies, pathological fibrosis, neuro-degeneration, and cardiovascular disease. in 2011, the company formed a strategic partnership with servier, a privately-run, french research
Organization | Viridian Therapeutics Inc |
Employees | 94 |
CEO | Mr. Stephen F. Mahoney J.D., MBA |
Industry | Healthcare |